{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-046052","form_type":"8-K","ticker":"KYTX","cik":"0001994702","company_name":"Kyverna Therapeutics, Inc.","filed_at":"2025-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.731526+00:00","generated_at":"2026-05-24T04:24:04.240286+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kyverna reports 2024 net loss $127.5M; cash runway into 2027; SPS trial 70% enrolled","bullets":["Net loss of $127.5M ($3.33 loss per share) for full year 2024 vs $60.4M loss in 2023.","Cash, equivalents and marketable securities $286.0M as of Dec 31, 2024; expected runway into 2027.","FDA aligned on registrational Phase 2 design for KYV-101 in stiff person syndrome; 70% enrolled, topline data 1H 2026.","Phase 2 interim data in myasthenia gravis and Phase 1 data in lupus nephritis expected in 2H 2025.","KYV-102 IND filing planned for 2H 2025; management team and board strengthened."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-046052","json":"https://secwatch.observer/filing/0000950170-25-046052.json","markdown":"https://secwatch.observer/filing/0000950170-25-046052.md","text":"https://secwatch.observer/filing/0000950170-25-046052.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1994702/000095017025046052/0000950170-25-046052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1994702/000095017025046052/kytx-20250327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T04:24:04.240286+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}